Clinical Trial Update: IL1-TRAP, Rilonacept, in Systemic Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports on IL1-TRAP (rilonacept) for systemic sclerosis (scleroderma), with the study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• Rilonacept (rilonacept)

Snippet

Sponsor: Boston University | Conditions: Scleroderma, Systemic Sclerosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-01